Inloggad som:

MK2140-004

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
MK2140-004
Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140 earlier VLS-101) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140 earlier VLS-101) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 2
Palliativ
Företag

Studien ändrades senast av: studyjohanna (2023-03-18)

Tillbaka till listan